<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26898">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02109315</url>
  </required_header>
  <id_info>
    <org_study_id>DIAB-01</org_study_id>
    <nct_id>NCT02109315</nct_id>
  </id_info>
  <brief_title>Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.</brief_title>
  <acronym>DIAB-01</acronym>
  <official_title>Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Cruceta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of liraglutide on vascular injury induced hypoglycemia in patients
      with type 1 diabetes mellitus. The vascular damage is evaluated at investigating the changes
      of endothelial function
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the effect of antioxidants (Vitamin C) on the vascular damage induced
      hypoglycemia in patients with type 1 diabetes. The vascular injury was evaluated in the same
      way as main objective. Checking the existence of a peripheral response to the action of
      GLP-1 due to oxidative stress.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed  measuring flow-mediated vasodilation (FMD) of the brachial artery.</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress markers</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Oxidative stress markers (nitrotyrosine and 8-iso prostaglandin F2 alpha plasma) in serum1 inflammation markers (serum sICAM-1, interleukin 6) 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Liraglutide  endovenous 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide endovenous de 0.6 mg.  one time a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamine C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamine C</intervention_name>
    <description>C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min</description>
    <arm_group_label>Vitamine C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide 6 mg</intervention_name>
    <description>Liraglutide endovenous de 0.6 mg. one time a day</description>
    <arm_group_label>Liraglutide  endovenous 6 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed and signed consent obtained before any trial-related activity . (
             Trial-related activities are those procedures that were not performed during routine
             medical examination of the patient) .

          -  Diagnosis of type 1 diabetes.

          -  Patients who do not have autonomic dysfunction , defined by ( 1).

          -  Patients not showing episodes of hypoglycemia unawareness based on the methods of
             Gold et al (2) .

          -  Patients without microvascular complications of diabetes.

          -  Patients without macrovascular complications of diabetes.

          -  Patients treated with multiple daily injections of insulin.

          -  No smoking .

          -  They should have a complete blood count, lipid profile, liver profile , renal profile
             and plasma electrolyte levels within normal values .

          -  No subject must have a history of hypertension or taking medication for high blood
             pressure .

          -  No subject should be taking medications known to affect the neuroendocrine responses
             to hypoglycemia or anti inflammatory

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to study some related products.

          -  Fertile women, lactating or pregnant, intend to become pregnant or who are not using
             adequate contraception, or men who have sexually active and are not sterilized
             surgically, those whose partners are not using a method adequate contraception.

          -  Clinical diagnosis of Type 2 Diabetes.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Ceriello A Ceriello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital clínic i provincial de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Cruceta M Cruceta, MD</last_name>
    <phone>932275400</phone>
    <phone_ext>4380</phone_ext>
    <email>acruceta@clinic.ub.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CTU Clínic (Clinical trial Unit) C Hospital Clínic</last_name>
    <phone>932275400</phone>
    <phone_ext>4380</phone_ext>
    <email>jmleon@clinic.ub.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Cruceta</last_name>
      <phone>932275400</phone>
      <phone_ext>4380</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Anna Cruceta</last_name>
      <phone>932275400</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>April 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundació Clínic per la Recerca Biomèdica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Project manager</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Alpha-Tocopherol</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
